Dr. Kenichi Furihata

Kenichi Furihata M.D., Ph.D.


Kenichi Furihata M.D., Ph.D.

Workplace & Position

Chair of the Keikokai Board of Trustees
Executive Director of P-One Clinic
Member of the SRL, Inc. Board of Directors
Guest Professor, Tokai University School of Medicine


1978 M.D. Keio University School of Medicine
May 31 1978 Passed the 65th National Examination for Medical Practitioners (Medical License # 241,063)
1985 Ph.D. Keio University School of Medicine

Professional History

1978-80 Intern, Department of Internal Medicine, Keio University Hospital
1980-82 In-hospital Doctor of Internal Medicine, Eiju General Hospital, (Taito Ward, Tokyo)
1982-85 Resident Physician, Keio University School of Medicine, (internal medicine, particularly hematology)
1985-88 Postdoctoral Research Fellow, Immunochemistry Laboratory, The Blood Center of Southeasthern Wisconsin, Milwaukee, WI, USA
1988-93 In-hospital Doctor of Internal Medicine (Hematology Team), 2nd Department of Internal Medicine, Shinshu University Hospital, (Matsumoto City, Nagano Prefecture)
May 1993 Instructor of Laboratory Medicine, Shinshu University School of Medicine
Sep 1993-
Jan 1999
Assistant Professor of Laboratory Medicine, Shinshu University School of Medicine, & Deputy Manager, Central Laboratory, Shinshu University Hospital
March 1999
Visiting Scientist, The Scripps Research Institute, La Jolla, CA, USA
Apr 1999-
Jan 2002
Senior Research Associate, The Scripps Research Institute, La Jolla, CA, USA
Feb 2002-
Oct 2003
Senior Research Scientist, Torrey Pines Institute for Molecular Studies, San Diego, CA, USA
Nov 2003-
Member of the SRL, Inc. Board of Directors
Jun 2005-
Feb 2007
Executive Director of P-One Clinic
March 2007-
Chair for the Keikokai Medical Corporation Board of Trustees, Executive Director of P-One Clinic

Career Overview

After graduating from the Keio University School of Medicine and passing the National Medical Practitioners Examination in spring of 1978, Dr. Kenichi Furihata completed a two year internal medicine internship at Keio University Hospital. As part of his education, Dr. Furihata worked for two years as a full-time doctor at the Eiju General Hospital Department of Internal Medicine in Taito Ward, Tokyo, mainly treating patients with hematological disorders.

In summer of 1982, he returned to the Department of Internal Medicine at Keio University School of Medicine to serve as a member of the Hematology Research Laboratory. There the doctor became engaged in research into the immunology of platelets and in January 1985 obtained his Ph.D. (Medical Doctor). Starting in February of the same year, he continued his research into platelet immunology at the Blood Center of Southeastern Wisconsin in Milwaukee (USA), under the supervision of Dr. Thomas J. Kunicki.

In March 1988, he returned to Japan and was employed from April of that year at the Shinshu University School of Medicine, 2nd Department of Internal Medicine. After working in the Blood Transfusion Department, he was transferred to laboratory medicine. Then in May 1993, he became an instructor (Deputy Manager of the Central Laboratory), and, in September of that year, moved up to assistant professor. Next, he participated in the launch of the first ever gene therapy department at a public university in Japan, and was put in charge of doping control at the Nagano Winter Olympics, hosted by Japan in February 1998.

Beginning in June of the same year, he became a Visiting Scientist at The Scripps Research Institute in San Diego, California (USA). There he engaged in molecular biological research into thrombi, with a focus on platelets. Next, due to a visa-related issues, he was transferred to the neighboring Torrey Pines Institute for Molecular Studies. After obtaining a green card in September 2003, he returned to Japan the following month (October) and began to serve as a member of the board of directors for SRL Inc., the largest clinical laboratory centre in Japan. At SRL, Dr. Furihata mainly oversaw the discovery and development of new testing methods. At the same time, in June 2005 he established a medical centre specialized in clinical trials, namely P-One Clinic, and became the executive director, a position he fills to this day. Moreover, in February 2007 he established the Keikokai Medical Corporation and continues to serve as chair on the board of trustees.

To summarize Dr. Kenichi Furihata’s career history up to the present, he has:

  • Experience as a clinical doctor of internal medicine (hematology)
  • Obtained results as a foundational researcher into immunology, molecular biology, cell culturing etc.
  • Managed the clinical laboratory department (which included genetic testing) of a university hospital
  • Established a gene therapy department (Shinshu University) and participated in providing medical care there
  • A broad perspective and personal network of connections developed through serving on the board of Japan’s largest clinical laboratory centre
  • Made contributions to drug development by overseeing a medical centre specialized in clinical studies
  • International sensibility acquired through living in America for a total of 8 1/2 years

Other Experience

Councillor, The Japanese Society of Laboratory Medicine (hematology)
1996-98 Director of Doping Control, The 1998 Winter Olympic Games in Nagano, Japan

Membership in Academic Associations

American Society of Hematology, International Society of Thrombosis and Haemostasis, The Japanese Society of Internal Medicine, The Japanese Society of Laboratory Medicine, The Japanese Society for Laboratory Hematology, The Japanese Society of Clinical Pharmacology and Therapeutics etc.

Academic Papers

01. Ikeda Y, Furihata K, Imai M, Sugiura K, Toyama K, Yamamoto M, Watanabe K, Ando Y: [Effect of anti-platelet tubulin antibody on platelet functions (author’s transl)]. Nippon Ketsueki Gakkai Zasshi 44:652, 1981
02. Kunicki TJ, Furihata K, Bull B, Nugent DJ: The immunogenicity of platelet membrane glycoproteins. Transfus Med Rev 1:21, 1987
03. Furihata K, Nugent DJ, Bissonette A, Aster RH, Kunicki TJ: On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa. Evidence for heterogeneity of glycoprotein IIIa. J Clin Invest 80:1624, 1987
04. Furihata K, Hunter J, Aster RH, Koewing GR, Shulman NP, Kunicki TJ: Human anti-PlE1 antibody recognizes epitopes associated with the alpha subunit of platelet glycoprotein Ib. Br J Haematol 68:103, 1988
05. Kickler TS, Herman JH, Furihata K, Kunicki TJ, Aster RH: Identification of Bakb, a new platelet-specific antigen associated with posttransfusion purpura. Blood 71:894, 1988
06. Kunicki TJ, Furihata K, Nugent D: Glycoprotein IIb-IIIa as an immunologic target. Curr Stud Hematol Blood Transfus :44, 1988
07. Simon TL, Collins J, Kunicki TJ, Furihata K, Smith KJ, Aster RH: Posttransfusion purpura associated with alloantibody specific for the platelet antigen, Pen(a). Am J Hematol 29:38, 1988
08. Ishida F, Saitoh H, Furihata K, Furuta S, Sonoyama M, Oshimi K: [Granular lymphocyte leukemia of natural killer cell type; association with 47 XY, +8 by interleukin 2 (IL-2)-stimulated chromosomal analysis]. Rinsho Ketsueki 31:1711, 1990
09. Kunicki TJ, Furihata K, Kekomaki R, Scott JP, Nugent DJ: A human monoclonal autoantibody specific for human platelet glycoprotein IIb (integrin alpha IIb) heavy chain. Hum Antibodies Hybridomas 1:83, 1990
10. Ishida F, Saji H, Maruya E, Furihata K: Human platelet-specific antigen, Siba, is associated with the molecular weight polymorphism of glycoprotein Ib alpha. Blood 78:1722, 1991
11. Murata M, Furihata K, Ishida F, Russell SR, Ware J, Ruggeri ZM: Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ib alpha involved in platelet transfusion refractoriness. Blood 79:3086, 1992
12. Wang R, Furihata K, McFarland JG, Friedman K, Aster RH, Newman PJ: An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system. J Clin Invest 90:2038, 1992
13. Tozuka M, Hidaka H, Miyachi M, Furihata K, Katsuyama T, Kanai M: Identification and characterization of apolipoprotein(AII-E2-AII) complex in human plasma lipoprotein. Biochim Biophys Acta 1165:61, 1992
14. Ogasawara K, Ueki J, Takenaka M, Furihata K: Study on the expression of ABH antigens on platelets. Blood 82:993, 1993
15. Ota H, Nakayama J, Fujimori Y, Furihata K, Katsuyama T, Moriyama S, Hata S, Ono K. Organized Differentiation of Tumor –Cells of Villous Adenomas of The Large- Intesitine. Acta Histochemica et Cytochemica 26:117, 1993
16. Yamamoto K, Hsu SP, Yoshida K, Ikeda S, Nakazato M, Shiomi K, Cheng SY, Furihata K, Ueno I, Yanagisawa N: Familial amyloid polyneuropathy in Taiwan: identification of transthyretin variant (Leu55–>Pro). Muscle Nerve 17:637, 1994/li>
17. Kawakami Y, Ueno I, Katsuyama T, Furihata K, Matsumoto H: Restriction fragment length polymorphism (RFLP) of genomic DNA of Moraxella (Branhamella) catarrhalis isolates in a hospital. Microbiol Immunol 38:891, 1994
18. Kawakami Y, Furuwatari C, Akahane T, Okimura Y, Furihata K, Katsuyama T, Matsumoto H: In vitro activity of arbekacin against clinical isolates of methicillin- resistant Staphylococcus aureus in a hospital. J Antibiot (Tokyo) 47:507, 1994
19. Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, Morita H, Hiyamuta S, Ikeda S, Shimizu N, Yanagisawa N: A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 9:267, 1995
20. Ishida F, Furihata K, Ishida K, Yan J, Kitano K, Kiyosawa K, Furuta S: The largest variant of platelet glycoprotein Ib alpha has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine145. Blood 86:1356, 1995
21. Ota H, Katsuyama T, Akamatsu T, Fujimori Y, Matsuzawa K, Ishii K, Honda T, Nakayama J, Furihata K, Ono K, Maeda K. Application of Mucin Histochemistry for Pathological Diagnosis – Expression of Gastric Phenotypes in Metaplastic and Neoplastic Lesions and Its Relation to The Organoid Differentiation. Acta Histochemica et Cytochemica 28:43, 1995
22. Ishida F, Furihata K, Ishida K, Kodaira H, Han KS, Liu DZ, Kitano K, Kiyosawa K: The largest isoform of platelet membrane glycoprotein Ib alpha is commonly distributed in eastern Asian populations. Thromb Haemost 76:245, 1996
23. Ikeda S, Yanagisawa N, Hanyu N, Furihata K, Kobayashi T: Coexistence of type I familial amyloid polyneuropathy and spinocerebellar ataxia type 1. Clinical and genetic studies of a Japanese family [letter]. J Neurol Neurosurg Psychiatry 60:586, 1996
24. Tozuka M, Ohta H, Hidaka H, Okumura N, Furihata K, Katsuyama T: Influence of apolipoprotein E phenotypes on total serum cholesterol in Japanese children. Clin Chim Acta 247:175, 1996
25. Tozuka M, Hidaka H, Okumura N, Ichikawa T, Furihata K, Katsuyama T: A case of immunoglobulin A-lambda conjugated with lactate dehydrogenase- 5 isoenzyme, causing an extremely high enzyme activity in serum. Clin Chem 42:1288, 1996
26. Kawa S, Yoshizawa K, Tokoo M, Imai H, Oguchi H, Kiyosawa K, Homma T, Nikaido T, Furihata K: Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 110:1605, 1996
27. Sakurai A, Katai M, Furihata K, Hashizume K: Gs alpha mutation may be uncommon in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 81:2394, 1996
28. Okumura N, Furihata K, Terasawa F, Nakagoshi R, Ueno I, Katsuyama T: Fibrinogen Matsumoto I: a gamma 364 Asp–>His (GAT–>CAT) substitution associated with defective fibrin polymerization. Thromb Haemost 75:887, 1996
29. Okumura N, Furihata K, Terasawa F, Ishikawa S, Ueno I, Katsuyama T: Fibrinogen Matsumoto II: gamma 308 Asn–>Lys (AAT–>AAG) mutation associated with bleeding tendency. Br J Haematol 94:526, 1996
30. Kawa S, Nikaido T, Aoki Y, Zhai Y, Kumagaya T, Furihata K, Fujii S, Kiyosawa K: Arotinoid mofarotene (RO40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines. Int J Cancer 72:906, 1997
31. Kawakami M, Okaneya T, Furihata K, Nishizawa O, Katsuyama T: Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2. Cancer Res 57:4167, 1997
32. Kobayashi H, Takemura Y, Miyachi H, Kawabata M, Mori S, Kawai Y, Furihata K, Sekiguchi S, Watanabe K: Quantitative analysis of human multidrug resistance 1 (MDR1) gene expression by nonisotopic competitive reverse transcriptase polymerase chain reaction assay. J Clin Lab Anal 11:258, 1997
33. Kawa S, Nikaido T, Aoki Y, Zhai Y, Kumagai T, Furihata K, Fujii S, Kiyosawa K: Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br J Cancer 76:884, 1997
34. Ichijo T, Matsumoto A, Kobayashi M, Furihata K, Tanaka E: Quantitative measurement of HCV RNA in the serum: a comparison of three assays based on different principles [published erratum appears in J Gastroenterol Hepatol 1998 May;13(5):following 550]. J Gastroenterol Hepatol 12:500, 1997
35. Furuya N, Kawa S, Akamatsu T, Furihata K: Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice. Gastroenterology 113:593, 1997
36. Kodaira H, Ishida F, Shimodaira S, Takamiya O, Furihata K, Kitano K: Resistance to activated protein C and Arg 506 Gln factor V mutation are uncommon in eastern Asian populations. Acta Haematol 98:22, 1997
37. Ota M, Katsuyama Y, Mizuki N, Ando H, Furihata K, Ono S, Pivetti-Pezzi P, Tabbara KF, Palimeris GD, Nikbin B, Davatchi F, Chams H, Geng Z, Bahram S, Inoko H: Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. Tissue Antigens 49:448, 1997
38. Nimura Y, Furuwatari C, Fujimori M, FUrimori Y, Nakata S, Ito K, Hama Y, Shingu K, Adachi W, Ogiso Y, Furihata K, Katsuyama T, Amano J. Germline mutations of the APC gene in two Japanese adenomatous polyposis patients. Jpn J Hum Genet. 42(3):433-9, 1997
39. Kumagai T, Malaty HM, Graham DY, Hosogaya S, Misawa K, Furihata K, Ota H, Sei C, Tanaka E, Akamatsu T, Shimizu T, Kiyosawa K, Katsuyama T: Acquisition versus loss of Helicobacter pylori infection in Japan: results from an 8-year birth cohort study. J Infect Dis 178:717, 1998
40. Misawa K, Kumagai T, Shimizu T, Furihata K, Ota H, Akamatsu T, Katsuyama T: A new histological procedure for re-evaluation of the serological test for Helicobacter pylori. Eur J Clin Microbiol Infect Dis 17:14, 1998
41. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 273:5678, 1998
42. Sato Y, Sakurai A, Miyamoto T, Hiramatsu K, Katai M, Furihata K, Hashizume K: Hyperfunctioning thyroid adenoma concomitant with papillary thyroid carcinoma, follicular thyroid adenoma and primary hyperparathyroidism. Endocr J 45:61, 1998
43. Kubota T, Sakurai A, Arakawa K, Shimazu M, Wakui K, Furihata K, Fukushima Y: Identification of two novel mutations in the OCRL1 gene in Japanese families with Lowe syndrome. Clin Genet 54:199, 1998
44. Karasawa Y, Kobayashi M, Nakano Y, Aoki Y, Kawa S, Kiyosawa K, Seki H, Kawasaki S, Furihata K, Itoh N: A case of glycogen storage disease type Ia with multiple hepatic adenomas and G727T mutation in the glucose-6-phosphatase gene, and a comparison with other mutations previously reported. Am J Gastroenterol 93:1550, 1998
45. Higuchi Y, Furihata K, Ueno I, Ishikawa S, Okumura N, Tozuka M, Sakurai N: Plasminogen Kanagawa-I, a novel missense mutation, is caused by the amino acid substitution G732R. Br J Haematol 103:867, 1998
46. Furuwatari C, Yagi A, Yamagami O, Ishikawa M, Hidaka E, Ueno I, Furihata K, Ogiso Y, Katsuyama T: A comprehensive system to explore p53 mutations. Am J Clin Pathol 110:368, 1998
47. Yazaki M, Yoshida K, Nakamura A, Furihata K, Yonekawa M, Okabe T, Yamashita N, Ohta M, Ikeda S: A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. J Neurol Sci 156:30, 1998
48. Furihata K, Drousiotou A, Hara Y, Christopoulos G, Stylianidou G, Anastasiadou V, Ueno I, Ioannou P: Novel splice site mutation at IVS8 nt 5 of HEXB responsible for a Greek- Cypriot case of Sandhoff disease. Hum Mutat 13:38, 1999
49. N. Hanaoka, K. Yoshida, A. Nakamura, K. Furihata, T. Seo, Y. Tani, J. Takahashi, S. Ikeda and N. Hanyu. A novel frameshift mutation in the McLeod syndrome gene in a Japanese family. J Neurol Sci, 165:6-9, 1999
50. Drousiotou A, Stylianidou G, Anastasiadou V, Christopoulos G, Mavrikiou E, Georgiou T, Kalakoutis G, Oladimeji A, Hara Y, Suzuki K, Furihata K, Ueno I, Ioannou PA, Fensom AH. Sandhoff disease in Cyprus: population screening by biochemical and DNA analysis indicates a high frequency of carriers in the Maronite community. Hum Genet.107: 12-7, 2000
51. Kobayashi H, Takemura Y, Kawai Y, Miyachi H, Kawabata M, Matsumura T, Yamashita T, Mori S, Furihata K, Shimodaira S, Motoyoshi K, Hotta T, Sekiguchi S, Ando Y, Watanabe K. Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukemic cells. J Lab Clin Med. 135:199-209, 2000
52. Miyabayashi H, Furihata K, Shimizu T, Ueno I, Akamatsu T. Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori. Helicobacter 5: 30-7, 2000
53. Furihata K, Clemetson KJ, Deguchi H, Kucniki TJ. Variation in Human Platelet Glycoprotein VI Content Modulates Glycoprotein VI–Specific Prothrombinase Activity. Arterioscler Thromb Vasc Biol 21: 1857-1863, 2001
54. Furihata K, Nugent DF, Kunicki TJ. Influence of Platelet Collagen Receptor Polymorphisms on Risk for Arterial Thrombosis. Archives of Pathology & Laboratory Medicine 126: 305–309, 2002
55. Furihata K, Kunicki TJ. Characterization of Human Glycoprotein VI Gene 5’ Regulatory and Promoter Regions. Arterioscler Thromb Vasc Biol 22: 1733-1739, 2002
56. OkanoA, Usuda N, Furihata K, Nakayama K, Bao Tin Q, Okamoto T, Suzuki T. Huntingtin-interacting protein-1-related protein of rat (rHIP1R) is localized in the postsynaptic regions. Brain Res. 967(1-2):210-25, 2003
57. Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, Reininger A, Ruggeri ZM, and Ware J. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003 Sep 1;102(5):1701-7.
58. Kanaji S, Kanaji T, Furihata K, Ware J, and Kunicki TJ. Convulxin binds to native, human glycoprotein Ib alpha. J Biol Chem. 2003 Oct 10;278(41):39452-60. Epub 2003 Jul 24.
59. Kunicki TJ, Cheli Y, Moroi M, Furihata K. The influence of N-linked glycosylation on the function of platelet glycoprotein VI. Blood. 2005 Oct 15;106(8):2744-9. Epub 2005 Jul 12.
60. Kato K, Furihata K, Cheli Y, Radis-Baptista G, Kunicki TJ.Effect of multimer size and a natural dimorphism on the binding of convulxin to platelet glycoprotein (GP)VI. J Thromb Haemost. 2006 May;4(5):1107-13.

Japanese Academic Papers Related to Clinical Pharmacology

  • 渡辺義人ほか、臨床試験における臨床検査値異常の判定基準案―基準変化値を指標とした 方法の提案―、臨床薬理38(2):81-88、2007
  • 降旗謙一ほか、アムロジピンOD錠 2.5mg 「トーワ」およびアムロジピンOD錠 5mg 「トー ワ」の健康成人における生物学的同等性、医学と薬学59(5):787-806、2008
  • 降旗謙一ほか、ビカルタミド錠80mg「NK」の健康成人男性における生物学的同等性試験、 医学と薬学61(2):189-195、2009